Blurbs

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE), Blueprint Medicines (BPMC) and Gossamer Bio (GOSS)

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Bluebird Bio (BLUEResearch Report), Blueprint Medicines (BPMCResearch Report) and Gossamer Bio (GOSSResearch Report).

Bluebird Bio (BLUE)

SVB Securities analyst Mani Foroohar maintained a Hold rating on Bluebird Bio today and set a price target of $10.00. The company’s shares closed last Wednesday at $6.78.

According to TipRanks.com, Foroohar is ranked 0 out of 5 stars with an average return of -12.9% and a 42.8% success rate. Foroohar covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, 4D Molecular Therapeutics, and Recursion Pharmaceuticals.

The word on The Street in general, suggests a Hold analyst consensus rating for Bluebird Bio with a $6.00 average price target, representing a -4.6% downside. In a report issued on August 5, Barclays also upgraded the stock to Hold with a $5.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Blueprint Medicines (BPMC)

SVB Securities analyst Andrew Berens maintained a Hold rating on Blueprint Medicines today and set a price target of $57.00. The company’s shares closed last Wednesday at $61.17.

According to TipRanks.com, Berens is a 4-star analyst with an average return of 2.6% and a 53.3% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Deciphera Pharmaceuticals.

Currently, the analyst consensus on Blueprint Medicines is a Moderate Buy with an average price target of $88.83, a 65.3% upside from current levels. In a report released yesterday, Piper Sandler also maintained a Hold rating on the stock.

Gossamer Bio (GOSS)

Barclays analyst Carter Gould maintained a Buy rating on Gossamer Bio today and set a price target of $18.00. The company’s shares closed last Wednesday at $13.75, close to its 52-week high of $14.48.

According to TipRanks.com, Gould is a 3-star analyst with an average return of 4.5% and a 52.3% success rate. Gould covers the Healthcare sector, focusing on stocks such as Travere Therapeutics, Applied Therapeutics, and Merck & Company.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Gossamer Bio with a $17.67 average price target, a 25.7% upside from current levels. In a report issued on August 10, Raymond James also maintained a Buy rating on the stock with a $18.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on BLUE:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos